The management of ocular surface squamous neoplasia (OSSN)

The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensu...

Full description

Saved in:
Bibliographic Details
Main Authors: Yeoh, Clarice H. Y., Lee, Jerome J. R., Lim, Blanche X. H., Sundar, Gangadhara, Mehta, Jodhbir S., Chan, Anita S. Y., Lim, Dawn K. A., Watson, Stephanie L., Honavar, Santosh G., Manotosh, Ray, Lim, Chris H. L.
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10356/169558
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-169558
record_format dspace
spelling sg-ntu-dr.10356-1695582023-07-30T15:37:57Z The management of ocular surface squamous neoplasia (OSSN) Yeoh, Clarice H. Y. Lee, Jerome J. R. Lim, Blanche X. H. Sundar, Gangadhara Mehta, Jodhbir S. Chan, Anita S. Y. Lim, Dawn K. A. Watson, Stephanie L. Honavar, Santosh G. Manotosh, Ray Lim, Chris H. L. Lee Kong Chian School of Medicine (LKCMedicine) Yong Loo Lin School of Medicine, NUS National University Health System Science::Medicine Ocular Surface Squamous Neoplasia Topical Chemotherapy The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN. Published version Publication fees associated with this article have been funded through the ExxonmobileNUS grant awarded to Chris Lim. 2023-07-24T06:49:21Z 2023-07-24T06:49:21Z 2023 Journal Article Yeoh, C. H. Y., Lee, J. J. R., Lim, B. X. H., Sundar, G., Mehta, J. S., Chan, A. S. Y., Lim, D. K. A., Watson, S. L., Honavar, S. G., Manotosh, R. & Lim, C. H. L. (2023). The management of ocular surface squamous neoplasia (OSSN). International Journal of Molecular Sciences, 24(1), 713-. https://dx.doi.org/10.3390/ijms24010713 1661-6596 https://hdl.handle.net/10356/169558 10.3390/ijms24010713 36614155 2-s2.0-85145979362 1 24 713 en International Journal of Molecular Sciences © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Medicine
Ocular Surface Squamous Neoplasia
Topical Chemotherapy
spellingShingle Science::Medicine
Ocular Surface Squamous Neoplasia
Topical Chemotherapy
Yeoh, Clarice H. Y.
Lee, Jerome J. R.
Lim, Blanche X. H.
Sundar, Gangadhara
Mehta, Jodhbir S.
Chan, Anita S. Y.
Lim, Dawn K. A.
Watson, Stephanie L.
Honavar, Santosh G.
Manotosh, Ray
Lim, Chris H. L.
The management of ocular surface squamous neoplasia (OSSN)
description The rise of primary topical monotherapy with chemotherapeutic drugs and immunomodulatory agents represents an increasing recognition of the medical management of ocular surface squamous neoplasia (OSSN), which may replace surgery as the standard of care in the future. Currently, there is no consensus regarding the best way to manage OSSN with no existing guidelines to date. This paper seeks to evaluate evidence surrounding available treatment modalities and proposes an approach to management. The approach will guide ophthalmologists in selecting the most appropriate treatment regime based on patient and disease factors to minimize treatment related morbidity and improve OSSN control. Further work can be done to validate this algorithm and to develop formal guidelines to direct the management of OSSN.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Yeoh, Clarice H. Y.
Lee, Jerome J. R.
Lim, Blanche X. H.
Sundar, Gangadhara
Mehta, Jodhbir S.
Chan, Anita S. Y.
Lim, Dawn K. A.
Watson, Stephanie L.
Honavar, Santosh G.
Manotosh, Ray
Lim, Chris H. L.
format Article
author Yeoh, Clarice H. Y.
Lee, Jerome J. R.
Lim, Blanche X. H.
Sundar, Gangadhara
Mehta, Jodhbir S.
Chan, Anita S. Y.
Lim, Dawn K. A.
Watson, Stephanie L.
Honavar, Santosh G.
Manotosh, Ray
Lim, Chris H. L.
author_sort Yeoh, Clarice H. Y.
title The management of ocular surface squamous neoplasia (OSSN)
title_short The management of ocular surface squamous neoplasia (OSSN)
title_full The management of ocular surface squamous neoplasia (OSSN)
title_fullStr The management of ocular surface squamous neoplasia (OSSN)
title_full_unstemmed The management of ocular surface squamous neoplasia (OSSN)
title_sort management of ocular surface squamous neoplasia (ossn)
publishDate 2023
url https://hdl.handle.net/10356/169558
_version_ 1773551326350802944